Infantile Pyloric Stenosis Clinical Trials

• Patient must be \>= 18 years and =\< 39 years of age at registration

• Patient must have a histologically confirmed diagnosis of primary cancer of any stage within 12 weeks (84 days) at registration

• Patient must not have a recurrence or second primary cancer

• Patients must not have basal cell skin carcinoma

• Patient must have received, be currently receiving or planning to receive treatment for cancer, including surgery and/or chemotherapy and/or radiation therapy

• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-3

• Patient must have a life expectancy \> 24 months

• Patient must be able to complete questionnaires in English or in Spanish

• Patient must have internet access through computer, tablet, or smartphone

• Patient must have an email address

• Patient must have a mobile phone able with text messaging capabilities

• Patient must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact)

• Patient must be able to provide informed consent

• Participation in clinical trials is not an exclusionary criterion in EAQ202. Patients may be dually enrolled in EAQ202 as well as in therapeutic trials, including those involving checkpoint inhibitors

⁃ NOTE: We understand that some therapeutic trials may also collect PRO data (e.g., the cross-National Clinical Trials Network \[NCTN\] S1826 study in which ECOG-ACRIN is participating), thus creating a potential for overburdening patients. We will be attentive to informing all patients of this potential overburdening as they consider a voluntary decision to register for EAQ202. We will coordinate with the PRO chair(s) of the therapeutic studies to ensure that the integrity of the PRO analyses be preserved